Nanobiotix SA
PAR:NANO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.962
7.54
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NANO stock under the Base Case scenario is 6.07 EUR. Compared to the current market price of 4.47 EUR, Nanobiotix SA is Undervalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Nanobiotix SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NANO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Nanobiotix SA
Balance Sheet Decomposition
Nanobiotix SA
Current Assets | 87.3m |
Cash & Short-Term Investments | 75.3m |
Receivables | 9.5m |
Other Current Assets | 2.6m |
Non-Current Assets | 6.6m |
Long-Term Investments | 299k |
PP&E | 6.3m |
Intangibles | 8k |
Current Liabilities | 49.9m |
Accounts Payable | 173k |
Accrued Liabilities | 7.4m |
Other Current Liabilities | 42.3m |
Non-Current Liabilities | 45.9m |
Long-Term Debt | 43.7m |
Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Nanobiotix SA
Revenue
|
36.2m
EUR
|
Operating Expenses
|
-61.3m
EUR
|
Operating Income
|
-25.1m
EUR
|
Other Expenses
|
-8.4m
EUR
|
Net Income
|
-33.5m
EUR
|
Free Cash Flow Analysis
Nanobiotix SA
EUR | |
Free Cash Flow | EUR |
Nanobiotix reported significant progress in its partnership with Janssen to develop NBTXR3, a potential first-in-class radioenhancer for solid tumors. This collaboration, potentially worth over $2.5 billion, has already triggered a $20 million milestone payment. The company’s cash balance for Q1 2024 stands at €58.9 million, extending the runway to Q3 2025. Key initiatives include transitioning the Phase III head and neck cancer trial sponsorship to Janssen, which received FDA approval to proceed with a Phase II lung cancer study. Beyond NBTXR3, Nanobiotix is advancing its Curadigm and Oocuity platforms for broader applications in cancer therapy.
What is Earnings Call?
NANO Profitability Score
Profitability Due Diligence
Nanobiotix SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Nanobiotix SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
NANO Solvency Score
Solvency Due Diligence
Nanobiotix SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Nanobiotix SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NANO Price Targets Summary
Nanobiotix SA
According to Wall Street analysts, the average 1-year price target for NANO is 11.83 EUR with a low forecast of 9.6 EUR and a high forecast of 16.8 EUR.
Dividends
Current shareholder yield for NANO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Contact
IPO
Employees
Officers
The intrinsic value of one NANO stock under the Base Case scenario is 6.07 EUR.
Compared to the current market price of 4.47 EUR, Nanobiotix SA is Undervalued by 26%.